# Choline in Pediatric Nutrition: Assessing Formula, Fortifiers and Supplements Across Age Groups and Clinical Indications

**Authors:** Wolfgang Bernhard, Anna Shunova, Ute Graepler-Mainka, Johannes Hilberath, Cornelia Wiechers, Christian F. Poets, Axel R. Franz

PMC · DOI: 10.3390/nu17101632 · 2025-05-09

## TL;DR

This paper examines choline content in pediatric nutrition products and highlights variability in choline supply for at-risk groups like preterm infants and children with cystic fibrosis.

## Contribution

The study provides a comparative analysis of choline and related nutrients in pediatric formulas and supplements across different age and clinical groups.

## Key findings

- Choline levels in preterm and term infant formulas are comparable up to 6 months.
- Products for toddlers and patients with CF, kidney, or Crohn’s disease show wide choline variability.
- Some products may contain additional choline from non-declared sources like milk components and lecithin.

## Abstract

Background: Sufficient choline supply is essential for tissue functions via phosphatidylcholine and sphingomyelin within membranes and secretions like bile, lipoproteins and surfactant, and in one-carbon metabolism via betaine. Choline requirements are linked to age and genetics, folate and cobalamin via betaine, and arachidonic (ARA) and docosahexaenoic (DHA) acid transport via the phosphatidylcholine moiety of lipoproteins. Groups at risk of choline deficiency include preterm infants, children with cystic fibrosis (CF) and patients dependent on parenteral nutrition. Fortifiers, formula and supplements may differently impact their choline supply. Objective: To evaluate added amounts of choline, folate, cobalamin, ARA and DHA in fortifiers, supplements and formula used in pediatric care from product files. Methods: Nutrient contents from commonly used products, categorized by age and patient groups, were obtained from public sources. Data are shown as medians and interquartile ranges. Results: 105 nutritional products including fortifiers, formula and products for special indications were analyzed. Choline concentrations were comparable in preterm and term infant formulas (≤6 months) (31.9 [27.6–33.3] vs. 33.3 [30.8–35.2] mg/100 kcal). Products for toddlers, and patients with CF, kidney or Crohn’s disease showed Choline levels from 0 to 39 mg/100 kcal. Several products contain milk components and lecithin-based emulsifiers potentially increasing choline content beyond indicated amounts. Conclusions: Choline addition is standardized in formula for term and preterm infants up to 6 months, but not in other products. Choline content may be higher in several products due to non-declared sources. The potential impact of insufficient choline supply in patients at risk for choline deficiency suggests the need for biochemical analysis of products.

## Linked entities

- **Chemicals:** choline (PubChem CID 305), folate (PubChem CID 135405876), cobalamin (PubChem CID 73415824), arachidonic acid (PubChem CID 444899), docosahexaenoic acid (PubChem CID 445580), betaine (PubChem CID 247), lecithin (PubChem CID 10425706)
- **Diseases:** cystic fibrosis (MONDO:0009061), kidney disease (MONDO:0001343), Crohn’s disease (MONDO:0005011)

## Full-text entities

- **Diseases:** choline deficiency (MESH:D002796), CF (MESH:D003550), Crohn's disease (MESH:D003424)
- **Chemicals:** Choline (MESH:D002794), cobalamin (MESH:D014805), ARA (-), folate (MESH:D005492), phosphatidylcholine (MESH:D010713), lecithin (MESH:D054709), sphingomyelin (MESH:D013109), carbon (MESH:D002244), betaine (MESH:D001622), acid (MESH:D000143)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12113760/full.md

---
Source: https://tomesphere.com/paper/PMC12113760